BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 26205347)

  • 21. Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells.
    Hau PM; Deng W; Jia L; Yang J; Tsurumi T; Chiang AK; Huen MS; Tsao SW
    J Virol; 2015 Jan; 89(1):652-68. PubMed ID: 25355892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.
    Daigle D; Gradoville L; Tuck D; Schulz V; Wang'ondu R; Ye J; Gorres K; Miller G
    J Virol; 2011 Jun; 85(11):5628-43. PubMed ID: 21411522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
    Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Screen for Epstein-Barr Virus Proteins That Inhibit the DNA Damage Response Reveals a Novel Histone Binding Protein.
    Ho TH; Sitz J; Shen Q; Leblanc-Lacroix A; Campos EI; Borozan I; Marcon E; Greenblatt J; Fradet-Turcotte A; Jin DY; Frappier L
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
    Novalić Z; Verkuijlen SAWM; Verlaan M; Eersels JLH; de Greeuw I; Molthoff CFM; Middeldorp JM; Greijer AE
    J Med Virol; 2017 Dec; 89(12):2207-2216. PubMed ID: 28853217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
    Kim SJ; Kim JH; Ki CS; Ko YH; Kim JS; Kim WS
    Ann Oncol; 2016 Mar; 27(3):508-13. PubMed ID: 26658891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
    Hsu CL; Kuo YC; Huang Y; Huang YC; Lui KW; Chang KP; Lin TL; Fan HC; Lin AC; Hsieh CH; Lee LY; Wang HM; Li HP; Chang YS
    Oncotarget; 2015 Oct; 6(31):31323-34. PubMed ID: 26416517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
    Conforti F; Davies ER; Calderwood CJ; Thatcher TH; Jones MG; Smart DE; Mahajan S; Alzetani A; Havelock T; Maher TM; Molyneaux PL; Thorley AJ; Tetley TD; Warner JA; Packham G; Ganesan A; Skipp PJ; Marshall BJ; Richeldi L; Sime PJ; O'Reilly KMA; Davies DE
    Oncotarget; 2017 Jul; 8(30):48737-48754. PubMed ID: 28467787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
    Li LH; Zhang PR; Cai PY; Li ZC
    Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapamycin enhances lytic replication of Epstein-Barr virus in gastric carcinoma cells by increasing the transcriptional activities of immediate-early lytic promoters.
    Wang M; Wu W; Zhang Y; Yao G; Gu B
    Virus Res; 2018 Jan; 244():173-180. PubMed ID: 29169830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells.
    Imesch P; Fink D; Fedier A
    Fertil Steril; 2010 Dec; 94(7):2838-42. PubMed ID: 20605144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.
    Ghosh SK; Perrine SP; Williams RM; Faller DV
    Blood; 2012 Jan; 119(4):1008-17. PubMed ID: 22160379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
    Feng WH; Hong G; Delecluse HJ; Kenney SC
    J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
    Countryman JK; Gradoville L; Miller G
    J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir.
    Jung EJ; Lee YM; Lee BL; Chang MS; Kim WH
    Cancer Lett; 2007 Mar; 247(1):77-83. PubMed ID: 16647201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
    Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
    Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-10 knockdown with siRNA enhances the efficacy of Doxorubicin chemotherapy in EBV-positive tumors by inducing lytic cycle via PI3K/p38 MAPK/NF-kB pathway.
    Gao L; Han H; Wang H; Cao L; Feng WH
    Cancer Lett; 2019 Oct; 462():12-22. PubMed ID: 31352079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus (EBV) Rta-mediated EBV and Kaposi's sarcoma-associated herpesvirus lytic reactivations in 293 cells.
    Chen YJ; Tsai WH; Chen YL; Ko YC; Chou SP; Chen JY; Lin SF
    PLoS One; 2011 Mar; 6(3):e17809. PubMed ID: 21423768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.
    Gorres KL; Daigle D; Mohanram S; Miller G
    J Virol; 2014 Jul; 88(14):8028-44. PubMed ID: 24807711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.